modelSonidegib

Diagram of Sonidegib

Extends from Pharmacolibrary.Drugs.ATC.L.L01XJ02.

Information

name:Sonidegib
ATC code:L01XJ02
route:oral
compartments:2
dosage:800mg
volume of distribution:9180L
clearance:3.51L/h
other parameters in model implementation

Sonidegib is a hedgehog pathway inhibitor used primarily for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not candidates for surgery or radiation therapy. It is an orally bioavailable, small-molecule inhibitor of the Smoothened (SMO) receptor. Sonidegib is approved for use in several countries including the US and EU.

Pharmacokinetics

Pharmacokinetic parameters reported in adult patients with advanced solid tumors following oral administration. Parameters reflect steady-state kinetics in cancer patients.

References

  1. Goel, V, et al., & Sellami, D (2016). Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 77(4) 745–755. DOI:10.1007/s00280-016-2982-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26898300

  2. Zhou, J, et al., & Sellami, D (2016). Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. British journal of clinical pharmacology 82(4) 1022–1029. DOI:10.1111/bcp.13038 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27277189

  3. Burness, CB, & Scott, LJ (2016). Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma. Targeted oncology 11(2) 239–246. DOI:10.1007/s11523-016-0418-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26867946

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)